Ryan Bond Biography and Net Worth

Chief Strategy Officer of Aclarion

Mr. Bond is the Chief Strategy Officer at Aclarion. Prior to his current role, he was the Vice President of Business Development, where he led business development, sales and marketing including a limited commercial launch of Aclarion’s cloud-based SaaS with early adopters in the US, EU, and UK.

Prior to his time at Aclarion, Mr. Bond was Director, Healthcare Solutions at NuVasive, a company in the global spine market. While at NuVasive, he led several strategic initiatives involving strategic partnerships, channel development, pricing, contracting, and sales training. Mr. Bond also worked with Accelero Health Partners (“Accelero”), a consulting firm focused on musculoskeletal service line development that wasacquired by Zimmer Holdings.

Mr. Bond serves on an Advisory Board to the College of Business at Ohio University, where he earned a Bachelor of Science Degree in Engineering from the Russ College of Engineering and Technology.

What is Ryan Bond's net worth?: The estimated net worth of Ryan Bond is at least $180.41 thousand as of August 13th, 2026. Mr. Bond owns 76,122 shares of Aclarion stock worth more than $180,409 as of October 8th. This net worth estimate does not reflect any other investments that Mr. Bond may own. Learn More about Ryan Bond's net worth.
How do I contact Ryan Bond?: The corporate mailing address for Mr. Bond and other Aclarion executives is 8181 Arista Place, Ste 100, Broomfield, CO, 80021. Aclarion can also be reached via phone at 833-275-2266. Learn More on Ryan Bond's contact information.
Has Ryan Bond been buying or selling shares of Aclarion?: Ryan Bond has not been actively trading shares of Aclarion during the last quarter. Most recently, on Thursday, August 13th, Ryan Bond bought 21,122 shares of Aclarion stock. The stock was acquired at an average cost of $2.37 per share, with a total value of $50,059.14. Following the completion of the transaction, the director now directly owns 76,122 shares of the company's stock, valued at $180,409.14. Learn More on Ryan Bond's trading history.
Who are Aclarion's active insiders?: Aclarion's insider roster includes Ryan Bond (Chief Strategy Officer), Gregory Gould (CFO), Gregory Gould (CFO), David Neal (Director), Brent Ness (CEO), Brent Ness (Chief Executive Officer, President, and Director), and Amanda Williams (Director). Learn More on Aclarion's active insiders.
Are insiders buying or selling shares of Aclarion?: During the last twelve months, Aclarion insiders bought shares 11 times. They purchased a total of 67,888 shares worth more than $176,647.43. The most recent insider tranaction occured on August, 17th when Director Amanda M Williams bought 5,857 shares worth more than $15,989.61. Insiders at Aclarion own 0.0% of the company. Learn More about insider trades at Aclarion.
Information on this page was last updated on 8/17/2026.

Ryan Bond Insider Trading History at Aclarion

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/13/2026	Buy	21,122	$2.37	$50,059.14	76,122

Ryan Bond Buying and Selling Activity at Aclarion

Aclarion Company Overview

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

Today's Range

Now: $2.35

$2.32

$2.41

50 Day Range

MA: $2.46

$2.02

$2.94

2 Week Range

Now: $2.35

$1.95

$12.03

Volume

21,449 shs

Average Volume

325,158 shs

Market Capitalization

$6.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2